The insect transmitted arboviruses among the flaviviruses pose a significant health risk to humans as observed during the recent Zika virus outbreak in South America ([@bb0025]). One of the most prominent members of this group of pathogens is Dengue virus (DENV), which exists in four serotypes, DENV1--4 ([@bb0005], [@bb0030]). While infection with one serotype confers protection against reinfection with the same serotype and is usually associated with only mild symptoms, exposure to a different serotype can cause severe disease, resulting in vascular leakage, uncontrolled cytokine levels and hemorrhagic fever. Especially delayed exposure to a second serotype from several months to three years after primary DENV infection increases the risk for severe disease ([@bb0035]). This suggests that waning DENV-specific immunity which diminishes protective cross-reactive immune responses against other serotypes can even exacerbate disease. Both the humoral and the cell-mediated arm of the immune system have been suspected to be responsible for this exacerbation. Cross-reactive, but not protective antibody responses might exacerbate infection by antibody-dependent enhancement (ADE) ([@bb0050]). In addition, original antigenic sin (OAS) has been proposed to focus T cell responses during infection with one serotype towards specificities that upon reinfection with another serotype are not protective, but get re-stimulated to produce immune pathological inflammation ([@bb0040]). Distinguishing between these two possibilities is of utmost importance to design broadly protective vaccine candidates ([@bb0020]).

Supporting the idea that T cell responses may be cross-reactive, the human MHC class I HLA-B\*0702 molecule was found to be associated with resistance to severe DENV infection upon exposure to different serotypes ([@bb0045]). Building on these findings the study by Elong Ngono and colleagues in this issue of *EBioMedicine* explores CD8^+^ T cell responses against DENV non-structural proteins (NS) 3, 4B and 5 in HLA-B\*0702 transgenic type I IFN receptor deficient mice ([@bb0010]). Even though the authors found diminished reactivity of some DENV2 epitope-induced CD8^+^ T cell responses against the respective sequences of the other serotypes, the respective CD8^+^ T cells were able to produce multiple cytokines upon re-stimulation with peptides from all serotypes. More importantly, challenge with DENV2 or DENV3 infection resulted in similar protection after vaccination with DENV2 or DENV1/3/4 derived peptides. These findings suggest that CD8^+^ T cell responses against DENV NS proteins can mediate protective cross-reactive immunity. However, it needs to be determined in the future if this is a particular feature of the protective HLA-B\*0702 allele that was used in this study or can be generalized to most HLA haplotypes.

If such protective cross-reactivity can, however, be demonstrated across most HLA haplotypes, then immunodominant CD8^+^ T cell antigens should be preferentially included into DENV-specific vaccination approaches. Following this line of thought, live-attenuated viral vectors, which stimulate CD8^+^ T cell responses most efficiently, might constitute a promising vaccine formulation ([@bb0020]). Along these lines, the live-attenuated vaccine of yellow fever virus (YV17D), another arbovirus of the flavivirus family, seems to be among the most successful vaccinations in humans ([@bb0015]). However, the NS antigens of DENV, which seem to provide dominant CD8^+^ T cell stimulation, should be included in such a protective T cell directed vaccination with live-attenuated viruses.
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